Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study
Autore:
Zhang, XY; Zhou, DF; Cao, LY; Zhang, PY; Wu, GY; Shen, YC;
Indirizzi:
Beijing Med Univ, Inst Mental Hlth, Beijing 100083, Peoples R China Beijing Med Univ Beijing Peoples R China 100083 100083, Peoples R China Beijing Huilongguan Hosp, Beijing, Peoples R China Beijing Huilongguan Hosp Beijing Peoples R China ijing, Peoples R China
Titolo Testata:
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
fascicolo: 6, volume: 16, anno: 2001,
pagine: 325 - 330
SICI:
0268-1315(200111)16:6<325:RVHITT>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
NEGATIVE SYNDROME SCALE; MULTICENTER; SEROTONIN; CLOZAPINE; RECEPTORS; DRUGS;
Keywords:
antipsychotic; extrapyramidal symptoms; haloperidol; risperidone; schizophrenia;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
32
Recensione:
Indirizzi per estratti:
Indirizzo: Zhang, XY Yale Univ, Sch Med, Neuropsychopharmacol Lab, SHM B-267,333 Cedar St, New Haven, CT 06520 USA Yale Univ SHM B-267,333 Cedar St New Haven CTUSA 06520 6520 USA
Citazione:
X.Y. Zhang et al., "Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study", INT CLIN PS, 16(6), 2001, pp. 325-330

Abstract

The purpose of this study was to compare the efficacy and safety of risperidone and haloperidol in treatment-resistant chronic schizophrenic patients. Subjects (n = 78) who met DSM-III criteria for schizophrenia were randomly assigned to receive 6 mg/day of risperidone or 20 mg/day of haloperidol for 12 weeks. Clinical efficacy was determined using the Positive and Negative Syndrome Scale (PANSS), and side-effects with the Treatment Emergent Symptom Scale (TESS). Risperidone produced a mean 39.8 +/- 24.1% reduction in total PANSS score compared to a mean 28.3 +/- 19.4% reduction in the haloperidol group (P < 0.05). Analysis of changes for the three subscores of the PANSS revealed that the general psychopathology and negative subscores weresignificantly improved in the risperidone group compared to the haloperidol group. As for the side-effects, the risperidone group showed a significantly lower TESS total score, as well as nervous system symptoms subscore andcardiovascular symptoms subscore, compared to the haloperidol group. Risperidone appears to be a more effective and better tolerated antipsychotic drug in treatment-refractory Chinese schizophrenia than haloperidol. (C) 2001Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 09:24:00